Display options
Cite
Kovaleva M, Johnson K, Steven J, et al. Therapeutic Potential of Shark Anti-ICOSL VNAR Domains is Exemplified in a Murine Model of Autoimmune Non-Infectious Uveitis. Front Immunol. 2017;8:1121doi: 10.3389/fimmu.2017.01121.
Kovaleva, M., Johnson, K., Steven, J., Barelle, C. J., & Porter, A. (2017). Therapeutic Potential of Shark Anti-ICOSL VNAR Domains is Exemplified in a Murine Model of Autoimmune Non-Infectious Uveitis. Frontiers in immunology, 81121. https://doi.org/10.3389/fimmu.2017.01121
Kovaleva, Marina, et al. "Therapeutic Potential of Shark Anti-ICOSL VNAR Domains is Exemplified in a Murine Model of Autoimmune Non-Infectious Uveitis." Frontiers in immunology vol. 8 (2017): 1121. doi: https://doi.org/10.3389/fimmu.2017.01121
Kovaleva M, Johnson K, Steven J, Barelle CJ, Porter A. Therapeutic Potential of Shark Anti-ICOSL VNAR Domains is Exemplified in a Murine Model of Autoimmune Non-Infectious Uveitis. Front Immunol. 2017 Sep 25;8:1121. doi: 10.3389/fimmu.2017.01121. eCollection 2017. PMID: 28993766; PMCID: PMC5622306.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2017 Sep 25;8:1121. doi: 10.3389/fimmu.2017.01121. eCollection 2017.

Therapeutic Potential of Shark Anti-ICOSL VNAR Domains is Exemplified in a Murine Model of Autoimmune Non-Infectious Uveitis.

Frontiers in immunology

Marina Kovaleva, Katherine Johnson, John Steven, Caroline J Barelle, Andrew Porter

Affiliations

  1. Elasmogen Ltd., Aberdeen, United Kingdom.
  2. John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle University, Newcastle, United Kingdom.
  3. Department of Molecular and Cell Biology, Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom.

PMID: 28993766 PMCID: PMC5622306 DOI: 10.3389/fimmu.2017.01121

Abstract

Induced costimulatory ligand (ICOSL) plays an important role in the activation of T cells through its interaction with the inducible costimulator, ICOS. Suppression of full T cell activation can be achieved by blocking this interaction and has been shown to be an effective means of ameliorating disease in models of autoimmunity and inflammation. In this study, we demonstrated the ability of a novel class of anti-ICOSL antigen-binding single domains derived from sharks (VNARs) to effectively reduce inflammation in a murine model of non-infectious uveitis. In initial selections, specific VNARs that recognized human ICOSL were isolated from an immunized nurse shark phage display library and lead domains were identified following their performance in a series of antigen selectivity and

Keywords: autoimmunity; biologic therapeutics; phage display; shark; single chain binding domain; uveitis; variable domain of shark new antigen receptor

References

  1. Am J Ophthalmol. 2000 Oct;130(4):492-513 - PubMed
  2. Mol Immunol. 2016 Jul;75:28-37 - PubMed
  3. Proteins. 2004 Apr 1;55(1):187-97 - PubMed
  4. Ophthalmic Res. 2008;40(3-4):169-74 - PubMed
  5. Int Immunol. 2000 Oct;12(10):1439-47 - PubMed
  6. J Immunol. 2002 Oct 15;169(8):4332-9 - PubMed
  7. Adv Exp Med Biol. 2009;655:49-62 - PubMed
  8. Virology. 2011 Mar 1;411(1):132-41 - PubMed
  9. Eur J Biochem. 2003 Sep;270(17):3543-54 - PubMed
  10. BMC Immunol. 2013 Apr 02;14:17 - PubMed
  11. J Immunol. 2006 Sep 15;177(6):3920-9 - PubMed
  12. Nat Rev Drug Discov. 2013 Feb;12(2):130-46 - PubMed
  13. Nature. 1999 Dec 16;402(6763):827-32 - PubMed
  14. J Exp Med. 2004 Jun 21;199(12):1659-69 - PubMed
  15. J Pharm Sci. 2006 Jun;95(6):1258-68 - PubMed
  16. Scand J Immunol. 2002 Aug;56(2):130-48 - PubMed
  17. Eur J Immunol. 2006 Nov;36(11):3071-81 - PubMed
  18. Ocul Immunol Inflamm. 2017 Jun;25(3):405-412 - PubMed
  19. Mol Immunol. 2003 Sep;40(1):25-33 - PubMed
  20. Methods Mol Biol. 2012;907:177-94 - PubMed
  21. Mol Immunol. 2011 Sep;48(15-16):2027-37 - PubMed
  22. Regul Toxicol Pharmacol. 2004 Dec;40(3):219-26 - PubMed
  23. World J Pharmacol. 2013;2(2):47-64 - PubMed
  24. Br J Ophthalmol. 2007 Mar;91(3):319-24 - PubMed
  25. Clin Ophthalmol. 2015 May 20;9:889-901 - PubMed
  26. Indian J Ophthalmol. 2013 Jun;61(6):277-83 - PubMed
  27. Br J Ophthalmol. 2004 Sep;88(9):1159-62 - PubMed
  28. J Immunol. 2000 May 1;164(9):4689-96 - PubMed
  29. Expert Opin Biol Ther. 2014 Oct;14(10):1527-39 - PubMed
  30. Ann Rheum Dis. 2010 Aug;69(8):1495-501 - PubMed
  31. Springer Semin Immunopathol. 1999;21(2):113-24 - PubMed
  32. Hybrid Hybridomics. 2004 Jun;23(3):168-75 - PubMed
  33. Hum Exp Toxicol. 2000 Apr;19(4):226-8 - PubMed
  34. Rheumatology (Oxford). 2008 Mar;47(3):339-44 - PubMed
  35. J Biol Chem. 2013 Jun 14;288(24):17408-19 - PubMed
  36. Mol Immunol. 2007 Mar;44(7):1775-83 - PubMed
  37. J Mol Biol. 2007 Mar 23;367(2):358-72 - PubMed
  38. Science. 2004 Sep 17;305(5691):1770-3 - PubMed
  39. Eur J Immunol. 2005 Mar;35(3):936-45 - PubMed
  40. BMC Immunol. 2012 Jun 11;13:29 - PubMed
  41. FEBS Lett. 2002 Apr 10;516(1-3):80-6 - PubMed
  42. J Immunol. 2009 Feb 1;182(3):1421-8 - PubMed
  43. MAbs. 2012 Nov-Dec;4(6):673-85 - PubMed
  44. BMC Biotechnol. 2007 Nov 19;7:78 - PubMed
  45. BioDrugs. 2017 Apr;31(2):135-142 - PubMed
  46. Mol Immunol. 2014 Jun;59(2):194-9 - PubMed
  47. Semin Immunopathol. 2014 Sep;36(5):581-94 - PubMed
  48. Ophthalmology. 2004 Mar;111(3):491-500; discussion 500 - PubMed
  49. Int Rev Immunol. 2013 Feb;32(1):76-96 - PubMed
  50. Orphanet J Rare Dis. 2012 Aug 29;7:57 - PubMed

Publication Types